These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 23415917)

  • 1. Biomarkers in T-cell therapy clinical trials.
    Lacey SF; Kalos M
    Cytotherapy; 2013 Jun; 15(6):632-40. PubMed ID: 23415917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers in T cell therapy clinical trials.
    Kalos M
    J Transl Med; 2011 Aug; 9():138. PubMed ID: 21851646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translation of neurological biomarkers to clinically relevant platforms.
    Hayes RL; Robinson G; Muller U; Wang KK
    Methods Mol Biol; 2009; 566():303-13. PubMed ID: 20058180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding clinical development of chimeric antigen receptor T cell therapies.
    de Wilde S; Guchelaar HJ; Zandvliet ML; Meij P
    Cytotherapy; 2017 Jun; 19(6):703-709. PubMed ID: 28433515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving the efficacy and safety of engineered T cell therapy for cancer.
    Shi H; Liu L; Wang Z
    Cancer Lett; 2013 Jan; 328(2):191-7. PubMed ID: 23022475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Muscle CARs and TcRs: turbo-charged technologies for the (T cell) masses.
    Kalos M
    Cancer Immunol Immunother; 2012 Jan; 61(1):127-35. PubMed ID: 22131062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted immunotherapy of cancer with CAR T cells: achievements and challenges.
    Lipowska-Bhalla G; Gilham DE; Hawkins RE; Rothwell DG
    Cancer Immunol Immunother; 2012 Jul; 61(7):953-62. PubMed ID: 22527245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase/2nd communication: promising strategies].
    Kuhlmann J
    Arzneimittelforschung; 2004; 54(6):307-13. PubMed ID: 15282874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Innovation and opportunity for chimeric antigen receptor targeted T cells.
    Melenhorst JJ; Levine BL
    Cytotherapy; 2013 Sep; 15(9):1046-53. PubMed ID: 23562306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro comparison of three different chimeric receptor-modified effector T-cell populations for leukemia cell therapy.
    Pizzitola I; Agostoni V; Cribioli E; Pule M; Rousseau R; Finney H; Lawson A; Biondi A; Biagi E; Marin V
    J Immunother; 2011; 34(6):469-79. PubMed ID: 21654519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical neuroproteomics and biomarkers: from basic research to clinical decision making.
    Shoemaker LD; Achrol AS; Sethu P; Steinberg GK; Chang SD
    Neurosurgery; 2012 Mar; 70(3):518-25. PubMed ID: 21866062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ten challenges for TB biomarkers.
    Ottenhoff TH; Ellner JJ; Kaufmann SH
    Tuberculosis (Edinb); 2012 Mar; 92 Suppl 1():S17-20. PubMed ID: 22441153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice.
    Westwood JA; Smyth MJ; Teng MW; Moeller M; Trapani JA; Scott AM; Smyth FE; Cartwright GA; Power BE; Hönemann D; Prince HM; Darcy PK; Kershaw MH
    Proc Natl Acad Sci U S A; 2005 Dec; 102(52):19051-6. PubMed ID: 16365285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T cell antigen receptor.
    Pameijer CR; Navanjo A; Meechoovet B; Wagner JR; Aguilar B; Wright CL; Chang WC; Brown CE; Jensen MC
    Cancer Gene Ther; 2007 Jan; 14(1):91-7. PubMed ID: 17024231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer immunotherapy.
    Zhou J; Zhong Y
    Cell Mol Immunol; 2004 Aug; 1(4):247-55. PubMed ID: 16225767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical development of T cell receptor gene therapy.
    Bendle GM; Haanen JB; Schumacher TN
    Curr Opin Immunol; 2009 Apr; 21(2):209-14. PubMed ID: 19321326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of T cell-based transcriptomics to identify three candidate biomarkers for monitoring anti-TGFbetaR therapy.
    Classen S; Muth C; Debey-Pascher S; Eggle D; Beyer M; Mallmann MR; Rudlowski C; Zander T; Pölcher M; Kuhn W; Lahn M; Schultze JL; Staratschek-Jox A
    Pharmacogenet Genomics; 2010 Mar; 20(3):147-56. PubMed ID: 20084050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive T-cell therapy of B-cell malignancies: conventional and physiological chimeric antigen receptors.
    Liu L; Sun M; Wang Z
    Cancer Lett; 2012 Mar; 316(1):1-5. PubMed ID: 22099879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
    Lee JW; Figeys D; Vasilescu J
    Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.